North America Bronchiectasis Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Sep 2021
  • North America
  • 350 Pages
  • No of Tables: 119
  • No of Figures: 50

North America Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral, and Inhalation ), End User (Hospitals, Clinics, Home Health Care, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast 2021 to 2028.

North America Bronchiectasis Market

 

Market Analysis and Insights: North America Bronchiectasis Market

North America bronchiectasis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.1% in the forecast period of 2021 to 2028 and is expected to reach USD 396.93 million by 2028. An increase in research regarding the bronchiectasis disease and availability of generic drugs in underdeveloped and developing countries are the major drivers which propelled the demand of the market in the forecast period.

Bronchiectasis comprises features such increasing need for safe and effective product will impact in launching new creation by the manufactures into the market which enhance its demand as well as increasing investment in research and development leads to the market growth. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative bronchiectasis products which is expected to provide various other opportunities in the bronchiectasis market. However, complications in the treatment of bronchiectasis and diagnostic challenges expected to restraint the market growth in the forecast period.

The Bronchiectasis market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Bronchiectasis Market North America Bronchiectasis Market Scope and Market Size

Bronchiectasis market is segmented on the based on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the bronchiectasis market is segmented into CF bronchiectasis and non-CF bronchiectasis. In 2021, non-CF bronchiectasis is expected to dominate the bronchiectasis market as it is highly prevalent form of bronchiectasis with higher cases reported among women and older population. 
  • On the basis of severity, the North America bronchiectasis market is segmented into mild to moderate and moderate-to-severe. In 2021, mild to moderate segment is expected to dominate the bronchiectasis market because on initiation of bronchiectasis patients experiences mild cough, airway blockage among others which sustain for life time. 
  • On the basis of type, the bronchiectasis market is segmented into diagnosis and treatment. In 2021, treatment segment is expected to dominate the bronchiectasis market because bronchiectasis is a life- long chronic disease. Severity of disease increase with increasing age and hence affected population relies on effective treatment approaches.
  • On the basis of drugs type, the bronchiectasis market is segmented into branded and generics. In 2021, branded segment is expected to dominate the bronchiectasis market because products offered by the many companies are the patent formulation and rising patient certitude towards branded formulations.
  • On the basis of route of administration, the bronchiectasis market is segmented into oral, parenteral, and inhalation. In 2021, inhalation segment is expected to dominate the bronchiectasis market because on high efficacy rate of inhalation drug formulation for treatment of respiratory disease. Moreover increasing innovation for development of smart inhalers equipped with drug dosage regulation is another factor boosting the market growth.
  • On the basis of end user, the bronchiectasis market is segmented into hospitals, clinics, home healthcare, and others. In 2021, hospitals segment is dominating the bronchiectasis market because most of the patients suffering from bronchiectasis visit hospitals in order to achieve accurate disease diagnosis and to experience effective treatment under the specialized professionals.
  • On the basis of distribution channel, the bronchiectasis market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy and others. In 2021, hospital pharmacy is expected to dominate the bronchiectasis market as hospital pharmacy offers wide ranges of drugs, therapies along with proper consultation and brand awareness.

North America Bronchiectasis Market Bronchiectasis Market Country Level Analysis

The bronchiectasis market is analyzed and market size information is provided on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.

The countries covered in the bronchiectasis market report are the U.S., Canada, Mexico.

Mild to moderate segment in North America region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing clinical trials and research development for prevention of respiratory diseases among the adults. U.S. is leading the growth of the North America market and Mild to moderate segment is dominating in this country because Bronchiectasis is a chronic, progressive and recurrent pulmonary infections these symptoms causes severe issues in patient day to day life. So, these symptoms seen in the initial stage of the bronchiectasis and treatment can be done on initial stage. Canada is expected to grow in the market due to rising government initiatives for treatment of rare diseases moreover Mexico is attaining lucrative growth due to rising cases of respiratory diseases and increase in awareness towards the better treatment options.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Awareness for Prevention of Bronchiectasis and Increasing Healthcare Expenditure are Boosting the Market Growth of Bronchiectasis

Bronchiectasis market also provides you with detailed market analysis for every country growth in Bronchiectasis industry with Bronchiectasis drugs sales, impact of advancement in the Bronchiectasis technology and changes in regulatory scenarios with their support for the Bronchiectasis market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Bronchiectasis Market Share Analysis

Bronchiectasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Bronchiectasis market.

The major companies which are dealing in the bronchiectasis are Abbott, HERSILL, Home Oxygen Company, Inogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc, Ache Laboratories Farmaceuticos S.A., Horizon Therapeutics plc, Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Trudell Medical International, GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis AG, Teva Pharmaceutical USA  Inc.(A Subsidiary of Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. Reddy’s Laboratories Ltd., Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.), Viatris Inc., Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Cipla Inc., Electromed, Inc., among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the bronchiectasis market.

For instance,

  • In June 2019, AstraZeneca received approval for Breztri Aerosphere (PT010) comprises of budesonide/glycopyrronium/ formoterol fumarate in Japan. The product is widely used for treatment of inflammation associated with lungs. This approval allowed the company to earn constant sales and to boost up the company’s revenue.
  • In March 2019, Novartis AG launched Ultibro Breezhaler and Seebri Breezhaler (COPD inhalers) which have been proved effective for treatment of inflammatory and infectious respiratory disease. This initiative boosted the company’s product portfolio and allowed it to expand its root in bronchiectasis market.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the Bronchiectasis market which also provides the benefit for organization to improve their offering for Bronchiectasis.

Customization Available: North America Bronchiectasis Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 NORTH AMERICA BRONCHIECTASIS MARKET, PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 HEALTHCARE EXPENDITURE IN NORTH AMERICA PER CAPITA (USD)

TABLE 4 THE PRICE OF X-RAY MACHINE

TABLE 5 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 28 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 51 U.S. BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 52 U.S. BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 53 U.S. BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 54 U.S. TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 55 U.S. TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 56 U.S. TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 57 U.S. TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 U.S. TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 59 U.S. TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 60 U.S. TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 U.S. TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 U.S. TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 U.S. TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 U.S. TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 U.S. TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 U.S. TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 67 U.S. DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 U.S. BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 69 U.S. BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 U.S. ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 U.S. PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 U.S. BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 73 U.S. BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 CANADA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 75 CANADA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 76 CANADA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 CANADA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 CANADA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 CANADA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 CANADA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 CANADA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 82 CANADA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 83 CANADA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 84 CANADA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 85 CANADA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 86 CANADA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 87 CANADA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 88 CANADA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 CANADA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 CANADA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 CANADA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 92 CANADA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 93 CANADA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 94 CANADA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 95 CANADA BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 96 CANADA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 97 MEXICO BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 98 MEXICO BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 99 MEXICO BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 100 MEXICO TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 101 MEXICO TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 MEXICO TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 103 MEXICO TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 MEXICO TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 MEXICO TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 106 MEXICO TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 107 MEXICO TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 108 MEXICO TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 109 MEXICO TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 MEXICO TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 MEXICO TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 112 MEXICO TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 113 MEXICO DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 114 MEXICO BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)

TABLE 115 MEXICO BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 116 MEXICO ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 117 MEXICO PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 118 MEXICO BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)

TABLE 119 MEXICO BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions